{"name":"DNAtrix, Inc.","slug":"dnatrix-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxPdXpjc0taaGhFWmNJLWNaZW9oTkdkZjJYaHJxdHpGWmRfYkNJU1ZRMVlpSXpWR0xLOFBxSFllZUZjTG9WRDJMYzlwNExadDQ4cklKTnBjZzlDUWRWX1A3QnJHTjBBanJZWjRwLUpRNEFtZFN5LTVqNGpQTEFnc0hfRG1TMHc3UWh0RE9zejFfbU9yOEFHSWFMS1d5QkhjS2d6N0xxcjM2VDZKQTVJazhGRDZJeExTTkl6allrQzJBb3FTSHhYN2cxaWl1akZZX3hzQTB1SG56bEJHb2YwZExJVzBWVVFBMVF1NlZrU3hHT1RGRFlHSW1xWWtFcEZnakt4ODZLVHFB?oc=5","date":"2026-03-30","type":"trial","source":"Barchart.com","summary":"Gastrointestinal Stromal Tumors Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com","headline":"Gastrointestinal Stromal Tumors Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPUGZEY2JIYWN3Y2dqeF9RYmtwWlBqa3Nxd1RodUNNOGI3THlfbzBLLVNGaUV1ZXZXMlkzTzluYmFBbzZnckdOSFd0NktuRUFLZkhvOWlwZWJTUkxSaDRfSkUyanFyWndvRnF3aTdJRjhIZWVabkE2NVJaZVNaaEJjeFc0dGIycnktSENVZTJOSGp0aFdxNzRNOEF5a0xOeGRJd01SLVBVTXR2bzNBU2xMYjhqVVMyU1lUOFE5Tzd6ellITkhqcUs3NHVwcEVOTUI5UHFZTTRiU3EtLU1OVkpOanZnVzVBa3lRaDA2X3hYUUtUM3ZqYWFScjFn?oc=5","date":"2026-03-21","type":"trial","source":"Barchart.com","summary":"Recurrent Glioblastoma Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight - Barchart.com","headline":"Recurrent Glioblastoma Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxOWnU3YnJCYzNuV0Y1RUFWQXpUYlFDTXhGa1hlMnhGRjAyRy01WXNJc05KSmd3RUVKZmV0aUxXWjVPbkV2dkhwb0s1NFdOWTRKSUVvYW8zdFNGSGJQSG5NMzFVQnB3WC12dS1ZQ3VPQnJ0a3pkVzdfTUlaMmV1bEp4VVJ1YS1QTmRBYlpJOGNYQ0c0M3VFcmZyeVhLTnJQcENYcmdkTHNWSmZiam45YlBwRVI0eHhJNkJPX0ZjdE1mZ2hOX0c5dVRNeUZtOU1LUzNpQjJhZ2NwNmpTQlBoSlh0VmpxbDBaWkZQX05YVmlvMFRzZXc2bnBRd2RrS3hNZFphTVhkT2hCc3BMUlliNHd3bXl3ZnJXa3M5NEFqR1ZNdHlERG_SAaMCQVVfeXFMTlp1N2JyQmMzbldGNUVBVkF6VGJRQ014RmtYZTJ4RkYwMkctNVlzSXNOSkpnd0VFSmZldGlMV1o1T25FdnZIcG9LNTRXTlk0SklFb2FvM3RTRkhiUEhuTTMxVUJwd1gtdnUtWUN1T0JydGt6ZFc3X01JWjJldWxKeFVSdWEtUE5kQWJaSThjWENHNDN1RXJmcnlYS05yUHBDWHJnZExzVkpmYmpuOWJQcEVSNHh4STZCT19GY3RNZmdoTl9HOXVUTXlGbTlNS1MzaUIyYWdjcDZqU0JQaEpYdFZqcWwwWlpGUF9OWFZpbzBUc2V3Nm5wUXdka0t4TWRaYU1YZE9oQnNwTFJZYjR3d215d2ZyV2tzOTRBakdWTXR5RERv?oc=5","date":"2026-02-04","type":"trial","source":"Bolsamania","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Bolsamania","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-27","type":"trial","source":"GlobeNewswire","summary":"Glioblastoma Market, an Area With High Trial Failure And - GlobeNewswire","headline":"Glioblastoma Market, an Area With High Trial Failure And","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBOWFlUUTk5WDR0dG9mUEp1VkZsemZ3YzN5c0E1d2dUNnNMeGdlUkdpODRXR0xFRVVtZV9EOTZITkpCN2RpLWhNVzQwaTNTSUYwTW9Xa0tZd0FmczZOTHVV?oc=5","date":"2023-05-15","type":"trial","source":"nature.com","summary":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial - nature.com","headline":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQWldVSXBwQ0RRQlJBTzFOaTBsVWtzZTd5MXcxMUlRY29jNTBicWVVSE1mTUxjWFoxWU1sQ253MkY4ejBvYWFfMlNZYWZkZWp5YkhXQVFZY0V3blZDdXNJR2hacGxZWDJsVFNTd1AzbmxQX3BhQTRPVjVydnhwR3hDOUNqclB6Yms4cUZZUjBxVFJickJTbjA4NllzR3dPVzRRUktObUpQWEdSMFVvT2JiWmoxamRKVWpNSEhnZWRvUjFmWVVr?oc=5","date":"2021-02-18","type":"pipeline","source":"PR Newswire","summary":"DNAtrix Appoints Industry Veteran Herb Cross to its Board of Directors - PR Newswire","headline":"DNAtrix Appoints Industry Veteran Herb Cross to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxQSmcxVmU2cEM5MEFoREVfVGswRUJ4c2tQMTR4MVJ3SkxBdklHRmtqaXNLRjdiOTd5eGxjM2FWX2RxZF9XZGRaMTVXNG5XRlVtaTNKUkZMem1LM1VpRG9NdkVyMk1QVXRtYmhEaTR1bTRnY3hsWkVfa3NuNnNZNEV2TnJ0eFZZUmZfY25HTlV0ZlZoLXFPVmJWUmhjS0RGNm9NOEt4VFhjTEluaUpUdmJLcmg4Tmp0V3lnZ2hHRkExbkpxU2plc2FCb0x4TWpCQ2xUb0lNYXBrYnBheVJVcndJ?oc=5","date":"2020-04-13","type":"earnings","source":"BioSpace","summary":"Sales Revenue in the Oncolytic Virus Immunotherapy Market to Witness Growth at Robust CAGR 12% During 2019 to 2029 - BioSpace","headline":"Sales Revenue in the Oncolytic Virus Immunotherapy Market to Witness Growth at Robust CAGR 12% During 2019 to 2029","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}